{"id":"pcv15-part-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain"},{"rate":null,"effect":"Injection site erythema"},{"rate":null,"effect":"Injection site swelling"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5095427","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains capsular polysaccharides from 15 serotypes of pneumococcus conjugated to a diphtheria toxoid protein carrier, which enhances immunogenicity and T-cell dependent responses. This conjugation approach improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against invasive pneumococcal disease and pneumococcal pneumonia caused by these serotypes.","oneSentence":"PCV15 is a pneumococcal conjugate vaccine that stimulates immune responses against 15 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:54.467Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in adults aged 18 years and older"},{"name":"Prevention of pneumococcal pneumonia in adults"}]},"trialDetails":[{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VAXNEUVANCE™"],"phase":"phase_3","status":"active","brandName":"PCV15 - Part B","genericName":"PCV15 - Part B","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"PCV15 is a pneumococcal conjugate vaccine that stimulates immune responses against 15 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in adults aged 18 years and older, Prevention of pneumococcal pneumonia in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}